PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Clinical Trials
5.0k
Trial Phases
6 Phases
Drug Approvals
69
Drug Approvals
Rimegepant Sulfate Orally Disintegrating Tablets
- Product Name
- 乐泰可
- Approval Number
- 国药准字HJ20240004
- Approval Date
- Jan 23, 2024
Ritlecitinib Tosylate Capsules
- Product Name
- 乐复诺
- Approval Number
- 国药准字HJ20230118
- Approval Date
- Oct 18, 2023
- Prev
- 1
- 2
- Next
Clinical Trials
Distribution across different clinical trial phases (3919 trials with phase data)• Click on a phase to view related trials
A Study to Learn if Multiple Doses of the Study Medicine Called Carbamazepine Changes How the Body Processes the Other Study Medicine PF-07248144
- First Posted Date
- 2025-09-30
- Last Posted Date
- 2025-09-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT07198035
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Other, Belgium
A Study to Learn About the Medicine Called Ritlecitinib in Adults With Severe Alopecia Areata in Real-world Settings
- First Posted Date
- 2025-09-30
- Last Posted Date
- 2025-09-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 123
- Registration Number
- NCT07200128
- Locations
- 🇺🇸
Pfizer, New York, New York, United States
A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: Portia (EE and LN) or equivalent oral tablet
- First Posted Date
- 2025-09-24
- Last Posted Date
- 2025-09-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT07190430
Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population
- Conditions
- Ulcerative Colitis
- Interventions
- Drug: Non-Interventional Study
- First Posted Date
- 2025-09-16
- Last Posted Date
- 2025-09-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 4000
- Registration Number
- NCT07177209
- Locations
- 🇬🇧
Pfizer, Walton Oaks, United Kingdom
A Study to Learn How Different Forms of the Study Medicine Called PF 08049820 Are Taken up Into the Bloodstream in Healthy Adults
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: PF-08049820 MR1Drug: PF-08049820 IRDrug: PF-08049820 MR2
- First Posted Date
- 2025-09-15
- Last Posted Date
- 2025-09-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT07172321
- Locations
- 🇺🇸
Pfizer Clinical Research Unit, New Haven, Connecticut, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 640
- Next
News
Biopharma M&A Activity Surges in Q3 2025 with $55.7 Billion in Acquisitions
The biopharmaceutical sector experienced a significant surge in high-value acquisitions during Q3 2025, with four of the year's five largest deals occurring in the past four months.
TAHO Pharma Submits World's First Apixaban Oral Dissolving Film to FDA for Stroke Survivors with Swallowing Difficulties
TAHO Pharmaceuticals has submitted a New Drug Application to the FDA for TAH3311, the world's first apixaban oral dissolving film designed for patients with swallowing difficulties.
Indivior Halts Marketing of Controversial Overdose Drug Opvee Following New York Settlement
Indivior has discontinued marketing of Opvee, its controversial overdose-reversal medication, following a settlement with New York Attorney General Letitia James after two years of poor sales and intense scrutiny.
FDA Halts New Drug Application Acceptance as Government Shutdown Begins
The FDA will not accept new drug applications during the government shutdown, though it can continue reviewing existing submissions funded by user fees.
Cue Biopharma Appoints Dr. Usman Azam as CEO, Pivots to Autoimmune Disease Focus with CUE-401
Cue Biopharma has appointed Dr. Usman Azam as President and CEO, effective September 29, 2025, bringing over 25 years of drug development experience including CAR-T cell therapy leadership at Novartis.
MannKind Appoints Dr. Ajay Ahuja as Chief Medical Officer to Advance Inhaled Therapeutics Pipeline
MannKind Corporation has appointed Dr. Ajay Ahuja as Chief Medical Officer, bringing over two decades of biopharmaceutical leadership experience to advance the company's inhaled therapeutics pipeline.
AstraZeneca Launches Direct-to-Consumer Platform with Up to 70% Drug Discounts Following Trump Administration Pressure
AstraZeneca announced it will offer its diabetes drug Farxiga and asthma drug Airsupra at discounts of up to 70% through a new direct-to-consumer platform launching October 1, 2025.
Pfizer Presents Breakthrough Cancer Data at ESMO 2025, Showcasing Unprecedented Survival Results
Pfizer will present data from more than 45 abstracts at ESMO 2025, including unprecedented survival results from the Phase 3 EV-303 trial evaluating PADCEV plus KEYTRUDA in muscle-invasive bladder cancer patients.
Pfizer Acquires Obesity Drug Developer Metsera in Strategic Move to Enter Weight Management Market
Pfizer has announced the acquisition of Metsera, a biotechnology company focused on developing obesity treatments, marking the pharmaceutical giant's strategic entry into the rapidly growing weight management market.
FAERS Analysis Reveals Lower Infection Risk with Ide-cel Compared to Other BCMA-Targeted Therapies in Multiple Myeloma
A retrospective analysis of FDA Adverse Event Reporting System (FAERS) data from 2021-2024 found that idecabtagene vicleucel (ide-cel) was associated with significantly lower infection rates compared to other BCMA-directed therapies in multiple myeloma patients.